Noticias y eventos de Xencor Inc (XNCR)

$22.850

-1.095 (-4.79%)Al cierre

Noticias de XNCR

2.010-19Newsfilter

Xencor to Host Webcast on XmAb819 Phase 1 Study Results

8.508-31Fool

Johnson & Johnson's Investment Portfolio Reveals Biotech Potential

4.008-26NASDAQ.COM

Xencor Stock Surpasses Analyst Target Price of $29.00

7.508-13NASDAQ.COM

Biotech Stocks Reach 52-Week Highs Driven by Positive Catalysts

9.508-05seekingalpha

Xencor Q2 Earnings Exceed Expectations with Strong Revenue Growth

7.507-30seekingalpha

Xencor Shares Rise After Settling Royalty Dispute with Alexion

7.507-22NASDAQ.COM

Biotech Stocks Reach 52-Week Highs Amid Clinical Trial Progress

7.507-21NASDAQ.COM

Biotech Stocks Reach 52-Week Highs Driven by Clinical Trials

8.507-17seekingalpha

Xencor Shares Surge 17% Following ESMO Presentation Announcement

2.007-17Newsfilter

Xencor's XmAb819 Clinical Trial Progress Announced

Ver más noticias

Eventos de XNCR

10/19 07:30

Xencor to Initiate XmAb819 Registration Study in 2027

Xencor to discuss results from the Phase 1 Study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma. XmAb819 Evaluation Across Advanced ccRCC and ENPP3+ Tumors: XmAb819 is being evaluated for the treatment of patients with advanced ccRCC and ENPP3+ tumors in a Phase 1 clinical study. Xencor is planning to initiate a registration-enabling study of XmAb819 monotherapy in advanced ccRCC in 2027. Currently: Expansion cohorts are evaluating intravenous doses to support selection of a dose for the planned Phase 3 pivotal study for patients with advanced ccRCC, Dose escalation of subcutaneous administration in advanced ccRCC is ongoing, A sub-study for patients with ENPP3+ advanced colorectal cancer, non-small cell lung cancer and papillary renal cell carcinoma opened to enrollment in the second quarter of 2026, and A sub-study for patients with intermediate- or poor-risk advanced ccRCC who have progressed after nivolumab in combination with ipilimumab as a first-line treatment opened to enrollment in the third quarter of 2026.

7/29 16:31

Xencor Reaches Settlement with Alexion for $105 Million

The company states: "Xencor announced its agreement with Alexion Pharma International Operations Limited, an Irish limited company, to resolve a commercial dispute related to U.S. royalties on Ultomiris. Under the Settlement Agreement, Xencor will receive $105 million in two equal payments, the first $52.5 million payment is anticipated in August 2026 and the second $52.5 million payment on the one-year anniversary of the executed Settlement Agreement, and Alexion will have no further obligation to pay royalties on U.S. sales of Ultomiris. Xencor expects to continue receiving royalties on ex-U.S. sales of Ultomiris under the existing terms of their license agreement."

6/4 14:20

FDA Pledges to Prevent Political Interference in Meeting with Rare Disease Nonprofits

Executives from 15 rare disease-focused nonprofits met on Wednesday with acting FDA Commissioner Kyle Diamantas and senior staff. In the meeting, Diamantas pledged to prevent political interference, Endpoint News' Zachary Brennan reports. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Biotech stocks include Replimune (REPL), Moderna (MRNA), Sarepta (SRPT), Xencor (XNCR), PTC Therapeutics (PTCT), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Design Therapeutics (DSGN), Ultragenyx (RARE), Dyne Therapeutics (DYN), Wave Life Sciences (WVE), MeiraGTx (MGTX), uniQure (QURE), Regenxbio (RGNX), Novavax (NVAX) and Lexeo Therapeutics (LXEO).

6/2 09:50

FDA Issues Draft Guidance for Gene Therapies

The U.S. Food and Drug Administration said it has issued draft guidance to help developers bring promising gene therapies to patients more efficiently by making greater use of existing scientific and regulatory knowledge. When finalized, the guidance will outline how sponsors can use publicly available information and established platform knowledge, including chemistry, manufacturing and controls data, nonclinical study results and clinical information, to streamline regulatory submissions for human gene therapy products that use genome editing in human somatic cells. "Today's action reflects the FDA's commitment to get safe and effective cell and gene therapies to patients faster, particularly those living with rare and life-threatening diseases who have few or no other treatment options," said Karim Mikhail, B. Pharm., M.S., Acting Director of the Center for Biologics Evaluation and Research. "By providing information on how companies may build on what is already known we are accelerating innovation without compromising the rigorous scientific standards that patients and the public depend on.Ultimately, this is about making sure that the promise of gene therapy reaches the patients who need it most, as quickly and safely as possible." This draft guidance supports the development of a wide range of cell and gene therapy products, including those that use genome editing, and is part of a broader set of complementary FDA actions in this area. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Biotech stocks include Replimune (REPL), Moderna (MRNA), Sarepta (SRPT), Xencor (XNCR), PTC Therapeutics (PTCT), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Design Therapeutics (DSGN), Ultragenyx (RARE), Dyne Therapeutics (DYN), Wave Life Sciences (WVE), MeiraGTx (MGTX), uniQure (QURE), Regenxbio (RGNX), Novavax (NVAX) and Lexeo Therapeutics (LXEO).

5/12 16:20

Major Averages Finish Mixed as Semiconductor Stocks Pull Back

The major averages had a mixed finish as semiconductor stocks pulled back following a massive multi-week run. AI-driven enthusiasm pushed the S&P 500 and Nasdaq to fresh records yesterday, but investors are now confronting a harder macro backdrop than previously anticipated. Meanwhile, crude is back above $100 as hopes for a durable U.S.-Iran ceasefire continue to deteriorate, with President Trump describing negotiations as being "on life support." Of note, the Iranian Fars news service reportedly said that Iran will not join the next round of U.S. talks without five preconditions being met.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:eBay'sboard rejected GameStop'sUnder Armourreported mostly in-line Q4 results andActivist investor Nelson Peltz's Trian Fund Management is seeking investor backing for a bid to take Wendy'sprivate,BuzzFeedannounced a proposed majority investment byFDA Commissioner Marty Makary has, according to multiple media reports citing administration officials2. WALL STREET CALLS:Lowe'sto Buy at CitiAutodeskat Buy from Neutral at BofARothschildToaston risk from DoorDashU.S. rolloutZoomInfoto Underweight at Piper Sandler and to Neutral-equivalent ratings and several other firmsWall Streetof drone-maker Aevexafter its recent IPO3. AROUND THE WEB:Microsofthas already earned back more than double the capital it invested in OpenAI in terms of new revenue from services related to OpenAI, The Information reportsGoogleand Elon Musk's SpaceX are in talks for a rocket launch deal amid efforts to put orbital data centers in space, WSJ saysAlphabet'sYouTube is looking to connect creators with sponsors to secure funding for shows before they launch, NY Times reportsSoftBankis partnering with South Korea's Cosmos Lab and DeltaX to mass produce next-gen data center batteries in Sakai, Japan at a scale of 1 GWh/year from FY27, Bloomberg reportsBoeing'ssuccess hinges on its successor to the 737, Bloomberg says4. MOVERS:Zebra Technologiesrose after providing areport for Q1SI-Bonewas higher after also providing areport for Q1Gitlabfell after announcing aZoomInfowas lower afterand reiterating its FY26 outlookGoProdeclined after reportingand withdrawing its FY26 guidance5. EARNINGS/GUIDANCE:Sea LimitedreportedBayerprovided areport for Q1Qnity Electronicsalso provided areport for Q1Tencent Musicreported ain Q1 earningsHims & Hers Healthprovidedbut raised its FY26 revenue guidanceINDEXES:The Dow rose 56.09, or 0.11%, to 49,760.56, the Nasdaq lost 185.92, or 0.71%, to 26,088.20, and the S&P 500 declined 11.88, or 0.16%, to 7,400.96.

Ver más eventos

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.